Loading…
Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017
Background Few large studies have assessed spironolactone treatment of adult female acne. Objectives To explore the role of spironolactone in the treatment of adult female acne. Methods We performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women e...
Saved in:
| Published in: | Journal of the European Academy of Dermatology and Venereology 2020-09, Vol.34 (9), p.2106-2110 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3252-13854e9cd7604bc36a8db93c19d4192cb1366879a93784b4f3402a1a2f7fbcc63 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3252-13854e9cd7604bc36a8db93c19d4192cb1366879a93784b4f3402a1a2f7fbcc63 |
| container_end_page | 2110 |
| container_issue | 9 |
| container_start_page | 2106 |
| container_title | Journal of the European Academy of Dermatology and Venereology |
| container_volume | 34 |
| creator | Roberts, E.E. Nowsheen, S. Davis, M.D.P. McEvoy, M.T. Newman, C.C. Sartori Valinotti, J.C. Sciallis, G.F. Torgerson, R.R. Wetter, D.A. |
| description | Background
Few large studies have assessed spironolactone treatment of adult female acne.
Objectives
To explore the role of spironolactone in the treatment of adult female acne.
Methods
We performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017.
Results
In total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two‐thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long‐term treatment with spironolactone (median duration, 13 months) and had few adverse effects.
Conclusions
Spironolactone is a safe and effective treatment of acne for women. |
| doi_str_mv | 10.1111/jdv.16302 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2359434922</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2359434922</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3252-13854e9cd7604bc36a8db93c19d4192cb1366879a93784b4f3402a1a2f7fbcc63</originalsourceid><addsrcrecordid>eNp1kLtOwzAUQC0EoqUw8APII0ik9SuJzYbKW0UshTVyHEe4SuMQO6268Q_8IV-CS4ANL1eWzj3SPQAcYzTG4U0WxWqME4rIDhhilvCIIk53wRAJkkRCxGIADpxbIIQwjvk-GFCCUo5FPAR23mrpl7r20JZQqlrDtfGv0DWmtbWtpPK21hdQwlb71rpGK29WOvxWRq-3O1TEUBZd5WEjvQkiB6WHj3Jj4bQytVHnkCCUfr5_EITTQ7BXysrpo585As831_PpXTR7ur2fXs4iRUlMIkx5zLRQRZogliuaSF7kgiosCoYFUTmmScJTIQVNOctZSRkiEktSpmWuVEJH4LT3Nq1967Tz2dI4patK1tp2LiM0FowyQUhAz3pUhftcq8usac1StpsMo2zbNwt9s---gT350Xb5Uhd_5G_QAEx6YG0qvfnflD1cvfTKL5vFg4I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2359434922</pqid></control><display><type>article</type><title>Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017</title><source>Wiley</source><creator>Roberts, E.E. ; Nowsheen, S. ; Davis, M.D.P. ; McEvoy, M.T. ; Newman, C.C. ; Sartori Valinotti, J.C. ; Sciallis, G.F. ; Torgerson, R.R. ; Wetter, D.A.</creator><creatorcontrib>Roberts, E.E. ; Nowsheen, S. ; Davis, M.D.P. ; McEvoy, M.T. ; Newman, C.C. ; Sartori Valinotti, J.C. ; Sciallis, G.F. ; Torgerson, R.R. ; Wetter, D.A.</creatorcontrib><description>Background
Few large studies have assessed spironolactone treatment of adult female acne.
Objectives
To explore the role of spironolactone in the treatment of adult female acne.
Methods
We performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017.
Results
In total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two‐thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long‐term treatment with spironolactone (median duration, 13 months) and had few adverse effects.
Conclusions
Spironolactone is a safe and effective treatment of acne for women.</description><identifier>ISSN: 0926-9959</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/jdv.16302</identifier><identifier>PMID: 32078195</identifier><language>eng</language><publisher>England</publisher><subject>Acne Vulgaris - drug therapy ; Adult ; Female ; Humans ; Minnesota ; Retrospective Studies ; Spironolactone ; Treatment Outcome</subject><ispartof>Journal of the European Academy of Dermatology and Venereology, 2020-09, Vol.34 (9), p.2106-2110</ispartof><rights>2020 European Academy of Dermatology and Venereology</rights><rights>2020 European Academy of Dermatology and Venereology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3252-13854e9cd7604bc36a8db93c19d4192cb1366879a93784b4f3402a1a2f7fbcc63</citedby><cites>FETCH-LOGICAL-c3252-13854e9cd7604bc36a8db93c19d4192cb1366879a93784b4f3402a1a2f7fbcc63</cites><orcidid>0000-0001-7174-5366</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32078195$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roberts, E.E.</creatorcontrib><creatorcontrib>Nowsheen, S.</creatorcontrib><creatorcontrib>Davis, M.D.P.</creatorcontrib><creatorcontrib>McEvoy, M.T.</creatorcontrib><creatorcontrib>Newman, C.C.</creatorcontrib><creatorcontrib>Sartori Valinotti, J.C.</creatorcontrib><creatorcontrib>Sciallis, G.F.</creatorcontrib><creatorcontrib>Torgerson, R.R.</creatorcontrib><creatorcontrib>Wetter, D.A.</creatorcontrib><title>Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><description>Background
Few large studies have assessed spironolactone treatment of adult female acne.
Objectives
To explore the role of spironolactone in the treatment of adult female acne.
Methods
We performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017.
Results
In total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two‐thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long‐term treatment with spironolactone (median duration, 13 months) and had few adverse effects.
Conclusions
Spironolactone is a safe and effective treatment of acne for women.</description><subject>Acne Vulgaris - drug therapy</subject><subject>Adult</subject><subject>Female</subject><subject>Humans</subject><subject>Minnesota</subject><subject>Retrospective Studies</subject><subject>Spironolactone</subject><subject>Treatment Outcome</subject><issn>0926-9959</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kLtOwzAUQC0EoqUw8APII0ik9SuJzYbKW0UshTVyHEe4SuMQO6268Q_8IV-CS4ANL1eWzj3SPQAcYzTG4U0WxWqME4rIDhhilvCIIk53wRAJkkRCxGIADpxbIIQwjvk-GFCCUo5FPAR23mrpl7r20JZQqlrDtfGv0DWmtbWtpPK21hdQwlb71rpGK29WOvxWRq-3O1TEUBZd5WEjvQkiB6WHj3Jj4bQytVHnkCCUfr5_EITTQ7BXysrpo585As831_PpXTR7ur2fXs4iRUlMIkx5zLRQRZogliuaSF7kgiosCoYFUTmmScJTIQVNOctZSRkiEktSpmWuVEJH4LT3Nq1967Tz2dI4patK1tp2LiM0FowyQUhAz3pUhftcq8usac1StpsMo2zbNwt9s---gT350Xb5Uhd_5G_QAEx6YG0qvfnflD1cvfTKL5vFg4I</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Roberts, E.E.</creator><creator>Nowsheen, S.</creator><creator>Davis, M.D.P.</creator><creator>McEvoy, M.T.</creator><creator>Newman, C.C.</creator><creator>Sartori Valinotti, J.C.</creator><creator>Sciallis, G.F.</creator><creator>Torgerson, R.R.</creator><creator>Wetter, D.A.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7174-5366</orcidid></search><sort><creationdate>202009</creationdate><title>Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017</title><author>Roberts, E.E. ; Nowsheen, S. ; Davis, M.D.P. ; McEvoy, M.T. ; Newman, C.C. ; Sartori Valinotti, J.C. ; Sciallis, G.F. ; Torgerson, R.R. ; Wetter, D.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3252-13854e9cd7604bc36a8db93c19d4192cb1366879a93784b4f3402a1a2f7fbcc63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Acne Vulgaris - drug therapy</topic><topic>Adult</topic><topic>Female</topic><topic>Humans</topic><topic>Minnesota</topic><topic>Retrospective Studies</topic><topic>Spironolactone</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roberts, E.E.</creatorcontrib><creatorcontrib>Nowsheen, S.</creatorcontrib><creatorcontrib>Davis, M.D.P.</creatorcontrib><creatorcontrib>McEvoy, M.T.</creatorcontrib><creatorcontrib>Newman, C.C.</creatorcontrib><creatorcontrib>Sartori Valinotti, J.C.</creatorcontrib><creatorcontrib>Sciallis, G.F.</creatorcontrib><creatorcontrib>Torgerson, R.R.</creatorcontrib><creatorcontrib>Wetter, D.A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roberts, E.E.</au><au>Nowsheen, S.</au><au>Davis, M.D.P.</au><au>McEvoy, M.T.</au><au>Newman, C.C.</au><au>Sartori Valinotti, J.C.</au><au>Sciallis, G.F.</au><au>Torgerson, R.R.</au><au>Wetter, D.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2020-09</date><risdate>2020</risdate><volume>34</volume><issue>9</issue><spage>2106</spage><epage>2110</epage><pages>2106-2110</pages><issn>0926-9959</issn><eissn>1468-3083</eissn><abstract>Background
Few large studies have assessed spironolactone treatment of adult female acne.
Objectives
To explore the role of spironolactone in the treatment of adult female acne.
Methods
We performed a retrospective case series assessing the efficacy of spironolactone treatment of a cohort of women evaluated at Mayo Clinic in Rochester, Minnesota, from 2007 through 2017.
Results
In total, 395 patients (median age, 32 years) received a median spironolactone dose of 100 mg daily. Approximately two‐thirds of patients (66.1%) had a complete response; 85.1% had a complete response or a partial response greater than 50%. Median times to initial response and maximum response were 3 and 5 months. Efficacy was observed across all severity subtypes of acne, including those with papulopustular and nodulocystic acne. Patients received long‐term treatment with spironolactone (median duration, 13 months) and had few adverse effects.
Conclusions
Spironolactone is a safe and effective treatment of acne for women.</abstract><cop>England</cop><pmid>32078195</pmid><doi>10.1111/jdv.16302</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-7174-5366</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0926-9959 |
| ispartof | Journal of the European Academy of Dermatology and Venereology, 2020-09, Vol.34 (9), p.2106-2110 |
| issn | 0926-9959 1468-3083 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2359434922 |
| source | Wiley |
| subjects | Acne Vulgaris - drug therapy Adult Female Humans Minnesota Retrospective Studies Spironolactone Treatment Outcome |
| title | Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007–2017 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T05%3A37%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20acne%20with%20spironolactone:%20a%20retrospective%20review%20of%20395%20adult%20patients%20at%20Mayo%20Clinic,%202007%E2%80%932017&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Roberts,%20E.E.&rft.date=2020-09&rft.volume=34&rft.issue=9&rft.spage=2106&rft.epage=2110&rft.pages=2106-2110&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/jdv.16302&rft_dat=%3Cproquest_cross%3E2359434922%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3252-13854e9cd7604bc36a8db93c19d4192cb1366879a93784b4f3402a1a2f7fbcc63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2359434922&rft_id=info:pmid/32078195&rfr_iscdi=true |